• China Isotope & Radiation posted operating revenue of RMB 2.99 billion, up 4.4% year over year.
• Net profit rose 2.1% to RMB 332.2 million; net profit attributable to owners edged down 1.2% to RMB 159 million.
• Operating profit climbed to RMB 463.49 million; operating margin widened 1 percentage point to 15.5%.
• Nuclear medicines revenue increased 4.6% to RMB 1.73 billion; nuclear medical equipment and related services jumped 46.8% to RMB 363.5 million.
• Management cited profit pressure from final tax-settlement adjustments, other-business restructuring, and exchange losses from international operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Isotope & Radiation Corporation published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12307090), on August 28, 2026, and is solely responsible for the information contained therein.